Peptide Vendor Shutdowns: The 2025-2026 Enforcement Map

The Short Version: What Happened in 2025-2026

Here is the enforcement picture in plain terms, drawn from the public record:

This is a developing enforcement story, and the dates and findings here reflect the public record. Nothing in this article is medical guidance, legal guidance, or a comment on any vendor not named in an official action.

The "Research Use Only" Loophole Was Never a Shield

For years, gray-market vendors leaned on a single phrase: "research use only," often paired with "not for human consumption." The idea was that labeling a vial as a laboratory reagent placed it outside the FDA's drug-approval framework. The enforcement record of 2025 and 2026 makes the legal reality plain. When a product is intended for human use, the FDA treats it as a drug regardless of the label on the box. An unapproved drug intended for people does not become a research chemical because a disclaimer says so.

This matters because almost none of these compounds are FDA-approved for the uses they were marketed around. [BPC-157](/peptides/bpc-157) and [TB-500](/peptides/tb-500), two of the most heavily sold research peptides, are not FDA-approved drugs. Marketing them with implied human-use benefits, even indirectly, is exactly what the agency objects to. The "research use only" framing did not stop the warehouse raid, the warning letters, or the closures. If anything, it became part of the evidence that products were being sold into a human-use market without approval.

The Enforcement Map, Vendor by Vendor

The table below summarizes the documented actions. Each row reflects a dated event in the public record, not speculation.

|---|---|---|

A few things stand out when you lay it out this way. First, the FDA actions and the DOJ actions are different tools aimed at the same problem. Warning letters and raids are regulatory pressure; forfeitures and guilty pleas are criminal and civil enforcement. Second, the September 2025 wave of more than 50 warning letters was not aimed at a single company. It was a sector-wide signal that the agency considered the "research use only" storefront model to be selling unapproved drugs. Third, the voluntary shutdowns of Science.bio and Peptide Sciences followed that pressure rather than preceding it, which tells you how the larger players read the environment.

The DOJ Cases: Forfeiture and a Guilty Plea

The Department of Justice actions add a sharper edge than the FDA letters. A warning letter is a demand to stop; a forfeiture and a guilty plea are consequences that have already landed.

In the Tailor Made Compounding matter, the DOJ secured a forfeiture of roughly 1.79 million dollars. A forfeiture of that size signals that authorities treated the proceeds as tied to unlawful conduct, not as ordinary business revenue. In the Paradigm Peptides matter, the company entered a guilty plea connected to SARMs products that were spiked with testosterone. That detail is worth pausing on. Selective androgen receptor modulators, or SARMs, are not the same class as testosterone, and a product spiked with an anabolic steroid is both a different compound than advertised and a controlled-substance problem. It is also a direct illustration of why product-identity uncertainty is the core risk of the gray market: the label and the contents did not match.

Neither of these cases is a comment on every vendor in the space. They are specific, named, adjudicated actions. But together with the FDA raid and the warning-letter wave, they describe an environment in which the old assumptions, that a disclaimer protects the seller and that the contents match the label, no longer hold.

What This Means for Identity and Trust

The single most important takeaway from the 2025-2026 enforcement map is not which company closed on which date. It is that the gray market never offered the identity and purity guarantees of an FDA-approved supply chain, and enforcement made that gap visible. The Paradigm Peptides plea is the clearest example: a product sold as one thing contained something else entirely.

For anyone trying to track a protocol responsibly, this is the heart of the matter. If you cannot verify what is actually in a vial, you cannot meaningfully interpret any biomarker change you observe, because you do not know what you were exposed to. A clean longitudinal record is only as trustworthy as the inputs behind it. None of this is a recommendation to use any unapproved compound. It is an explanation of why product identity, not just dosing, sits at the center of the conversation. For plain-language overviews of individual compounds and their regulatory status, you can browse the [peptide library](/peptides) and the [best peptides overview](/best-peptides), both written to inform rather than to sell.

What This Does Not Tell You to Do

This article will not point you to surviving vendors, name any source as "safe," or suggest a way to keep obtaining products that enforcement has targeted. That is outside the scope of an education and tracking resource, and it would run against the spirit of the regulatory record described here. The closure of one vendor says nothing reassuring about another, and we make no claim about any company not named in an official action. Speculating about who is "clean" would be both unfounded and unfair.

The constructive move, if you are navigating this landscape, is the same one it always was: bring good data and honest questions to a licensed clinician. Compounds like [semaglutide](/peptides/semaglutide) and [tirzepatide](/peptides/tirzepatide) are available as FDA-approved products through prescribers, which is a fundamentally different situation than buying a "research use only" vial online. For anything clinical, defer to your provider or prescriber.

What to Track: Biomarkers Worth Monitoring

Whether you are following the peptide space from the sidelines or working with a clinician on an approved protocol, the value of a clean, organized health record does not change. People who use peptides or related compounds, in partnership with their providers, commonly keep an eye on a set of safety-relevant and metabolic markers over time. The following are biomarkers that researchers and clinicians frequently discuss in this context. None of this is a recommendation to test or treat. It is a list of what is commonly tracked so you can organize your own data and discuss it with your provider.

Tracking these consistently, rather than as scattered one-off results, is what makes the data genuinely useful in a clinical conversation. A single value is a snapshot; a trend line tells a story. You can browse the full [biomarker library](/biomarkers) for plain-language explanations of each test, and clinics that manage these conversations can learn how teams use the platform on the [clinics page](/clinics).

[Track your protocol and labs in one place with MyProtocolStack.](/auth/login?mode=signup)

How This Fits the Broader 2026 Picture

The vendor shutdowns do not stand alone. They sit alongside the broader tightening of FDA and DOJ enforcement against gray-market peptide selling that defined 2025 and 2026. The shared logic across all of it is that the labeling workarounds that once allowed broad gray-market access have narrowed back toward the standard framework, in which FDA-approved products are the default and unapproved compounds carry real legal and identity risk.

For people tracking their health seriously, the practical takeaway is steady regardless of how any single case lands: keep your records clean and provider-ready, verify what you can, and treat product identity as a first-order question rather than an afterthought. You can explore structured overviews of individual compounds in the [peptide library](/peptides) and compare regulatory context across the catalog from there.

Frequently Asked Questions

Which peptide vendors shut down in 2025 and 2026?

Two of the largest U.S. gray-market peptide vendors closed during this period. Science.bio closed on January 27, 2026, and Peptide Sciences voluntarily shut down on March 6, 2026. These followed broader FDA pressure, including a June 2025 warehouse raid on Amino Asylum and a wave of more than 50 FDA warning letters in September 2025. This reflects the public enforcement record and is not a comment on any vendor not named in an official action.

What FDA and DOJ actions drove the peptide vendor shutdowns?

The FDA raided Amino Asylum's warehouse in June 2025 and issued more than 50 warning letters in September 2025, signaling that "research use only" storefronts were selling unapproved drugs. Separately, the DOJ secured a roughly 1.79 million dollar forfeiture from Tailor Made Compounding and a guilty plea from Paradigm Peptides tied to SARMs products that were spiked with testosterone. Together these regulatory and criminal actions defined the contraction.

Did the "research use only" label protect these vendors?

No. When a product is intended for human use, the FDA treats it as a drug regardless of a "research use only" or "not for human consumption" label. The 2025-2026 enforcement record shows that the disclaimer did not prevent the warehouse raid, the warning letters, or the closures. Many of these compounds, including BPC-157 and TB-500, are not FDA-approved drugs.

Why does product identity matter so much in the gray market?

Because the label and the contents do not always match. The Paradigm Peptides guilty plea involved SARMs products that were spiked with testosterone, meaning the product contained something different from what was advertised. If you cannot verify what is actually in a vial, you cannot meaningfully interpret any biomarker change, and you may be exposed to a controlled substance you did not intend to take.

I have been following this space. What should I do?

For anything clinical, talk with a licensed prescriber or provider, who can discuss FDA-approved options that exist within a verified supply chain. MyProtocolStack does not provide medical advice and cannot tell you what to take or where to obtain it. What you can do on your own is keep an organized, longitudinal record of your protocol and relevant lab markers over time, so any provider conversation is grounded in good data.

Sources

1. The Peptide Catalog, "Peptide Vendors That Shut Down in 2025-2026." https://thepeptidecatalog.com/articles/peptide-vendors-shut-down-2025-2026

2. Peptide Dossier, "Peptide Sciences Shutdown." https://peptidedossier.com/guides/peptide-sciences-shutdown/

3. U.S. Food and Drug Administration, Warning Letter, "Gram Peptides (721806), March 31, 2026." https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*